Business
Sight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023
MENLO PARK, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company
About this update from Sight Sciences, Inc.
[{"type":"text","content":"MENLO PARK, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (\"Sight Sciences\" or the \"Company\"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today reported financial results for the second quarter ended June 30, 2023 and reaffirmed guidance for full year 2023. Recent Business and Financial Highlights Generated record second quarter 2023 total revenue of $23.5 million, an increase of 36% compared to the prior year periodAchieved total gross margin of 85.6% in the second quarter of 2023 compared to 84.1% in the prior year period Dry Eye Highlights The SAHARA randomized controlled clinical trial successfully met its primary objective signs endpoint at six months, showing that interventional eyelid procedures enabled by TearCare® technology provided statistically significant improvements as compared to Restasis1 in tear break up time (TBUT), a key measure of aqueous retention, tear stability and the tear film’s ability to protect the ocular surfaceThe SAHARA trial also observed that the improvement in Ocular Surface Disease Index (OSDI) at six months among the TearCare group was non-inferior to the Restasis group; OSDI was the primary subjective symptoms endpoint in the study Throughout the trial, patients in the TearCare group also demonstrated clinically and statistically significant improvements in all ten signs and symptoms endpoints at every measurement interval evaluated to date (one week, one month, three months, and six months) Surgical Glaucoma Highlights Procedures enabled by the OMNI® Surgical System technology were categorized as medically necessary and covered by Cigna Healthcare effective June 15, 2023, expanding access to OMNI for close to 15 million covered livesPublished two-year multicenter study results showing sustained reductions in both intraocular pressure (IOP) and glaucoma medication use in mild-moderate primary open angle glaucoma patients treated with the OMNI Surgical System technologyAnnounced 12-month results from the first minimally invasive glaucoma surgery (MIGS) comparative analysis of real-world data from the American Academy of Ophthalmology IRIS® Registry, reporting that patients treated with OMNI in combination with cataract surgery experienced the greatest ...